TCGA-AC-A6IW-01A-12R-A33J-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 14
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.650
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_ALPHA_RESPONSE+0.560
- INTERFERON_GAMMA_RESPONSE+0.510
- MYC_TARGETS_V1+0.470
- IL6_JAK_STAT3_SIGNALING+0.420
- E2F_TARGETS+0.410
- INFLAMMATORY_RESPONSE+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- G2M_CHECKPOINT+0.300
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- PROTEIN_SECRETION-0.440
- UV_RESPONSE_DN-0.430
- ANGIOGENESIS-0.370
- TGF_BETA_SIGNALING-0.370
- ESTROGEN_RESPONSE_EARLY-0.360
- ANDROGEN_RESPONSE-0.310
- ESTROGEN_RESPONSE_LATE-0.300
- BILE_ACID_METABOLISM-0.230
- CHOLESTEROL_HOMEOSTASIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.945 |
| 2 | TCGA-B6-A0I2-01A-11R-A034-07 | — | E | 0.895 |
| 3 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.894 |
| 4 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.894 |
| 5 | TCGA-A2-A3XT-01A-11R-A22U-07 | — | E | 0.887 |
| 6 | MBCproject_0095_T3_RNA | — | E | 0.886 |
| 7 | 20100125.TNBC | — | E | 0.886 |
| 8 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.883 |
| 9 | 20030081.TNBC | — | D | 0.882 |
| 10 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |